Movement Alert|Synopsys Rises 3.35% in Regular Trading, Q3 Earnings Beat Expectations with Raised Full-Year Guidance

Market Focus
Aug 27

On August 27, Synopsys rose 3.35% in regular trading, trading at $422.31/share, with turnover of $166 million. The rebound follows an initial after-hours dip as investors reassessed the company's strong fiscal Q3 results and upwardly revised outlook.

Synopsys reported fiscal Q3 non-GAAP EPS of $3.91, beating the consensus estimate of $3.67 by 6.5%, while revenue came in at $2.48 billion versus $2.44 billion expected, representing 42% year-over-year growth. The company raised its full-year FY2026 revenue guidance to $9.69 billion-$9.74 billion and EPS guidance to $15.04-$15.10, both above prior forecasts. Q4 guidance of $2.53B-$2.58B in revenue and $4.10-$4.16 EPS also exceeded analyst expectations. Management highlighted EDA accelerating toward double-digit growth, Design IP returning to a growth trajectory, and Ansys integration synergies beginning to materialize after the one-year anniversary of the acquisition.

Mizuho adjusted its price target on Synopsys to $550 from $600, maintaining an overweight stance, while the analyst consensus mean target stands at $554.52.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10